CompletedNCT04531189
Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease
Studying Wilson disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ultragenyx Pharmaceutical Inc
- Principal Investigator
- Ultragenyx Medical DirectorUltragenyx Pharmaceutical
- Enrollment
- 16 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2020 – 2022
Study locations (6)
- Yale University School of Medicine, New Haven, Connecticut, United States
- Jackson Memorial Hospital Miami Transplant Unit University of Miami Miller School of Medicine, Miami, Florida, United States
- Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
- University of Michigan Michigan Medicine Hepatology Clinic Taubman Center, Ann Arbor, Michigan, United States
- Seattle Children's Hospital, Seattle, Washington, United States
- Universitätsklinikum Heidelberg, Heidelberg, Baden-Wurttemberg, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04531189 on ClinicalTrials.govOther trials for Wilson disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07301216Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot StudyYale University
- RECRUITINGEARLY PHASE1NCT07240896A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)DSciLab Co., Ltd.
- RECRUITINGNCT07226622Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical TrialPrime Medicine, Inc.
- RECRUITINGNANCT06945081Wilson's Disease Treated With D-Penicillamine: Characterization of Skin Damage Secondary to Treatment by Measuring Skin ElasticityCentre Hospitalier Universitaire de Saint Etienne
- ENROLLING BY INVITATIONNCT07159581Gene Therapy for Wilson Disease Evaluated by 64Cu PET/CTThomas Damgaard Sandahl
- RECRUITINGNCT06430359Circadian Variation of Urinary Copper Excretion in Wilson Disease PatientsHospices Civils de Lyon
- RECRUITINGEARLY PHASE1NCT06650319A Clinical Study to Evaluate the Safety and Efficacy of LY-M003 Injection in Patients With Wilson DiseaseChaohui Yu
- RECRUITINGNCT05444127Oral Health and Wilson's Disease: SOMAWIFondation Ophtalmologique Adolphe de Rothschild